LUNG CANCER
Vysis ALK Break Apart FISH Probe Kit
For more information, contact Abbott.
For more information, contact Abbott.
PRODUCT NAME | UNIT SIZE | ORDER NUMBER | GTIN |
---|
Intended Use
The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens to aid in identifying those patients eligible for treatment with Xalkori® (Crizotinib)
Warnings and Limitations
To learn more about Vysis ALK Break Apart FISH Probe Kit please visit: https://www.molecular.abbott/int/en/products/oncology/vysis-alk-break-apart-fish-probe-kit
When hybridized with the LSI ALK Dual Color, Break Apart Rearrangement Probe, the 2p23 ALK region in its native state will be seen as two immediately adjacent or fused orange/green (yellow) signals (2F). However, if a t(2;5) or other chromosome rearrangement at the 2p23 ALK breakpoint region has occurred, one orange and one green signal will be seen, while the native ALK region will remain as an orange/ green fusion signal (1O1G1F). The hybridization result of the LSI ALK Dual Color, Break Apart Rearrangement Probe containing the t(2;5) translocation will be the centromeric green probe remaining at 2p23, while the telomeric orange signal that covers the region is translocated to 5q35 on the derivative chromosome.
Abnormal Hybridization: Hybridization image demonstrating a break in the ALK locus. Vysis ALK Break abnormal (positive) signal pattern is represented by 1 green, 1 red and 1 fusion signal.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.